세계의 결합 백신 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 브랜드별, 질환별, 병원균별, 환자별, 지역별, 부문별 예측(2024-2030년)

Conjugate Vaccine Market Size & Trends

The global conjugate vaccine market size was estimated at USD 19.01 billion in 2023 and is expected to grow at a CAGR of 9.60% from 2024 to 2030. The rising incidence of infectious diseases globally is a significant driver for the growth of the conjugate vaccines market. Conjugate vaccines help protect against several serious bacterial diseases, including Haemophilus influenzae disease b (Hib, Pneumococcal infections, and Meningococcal infections. According to the CDC, pneumococci, specifically Streptococcus pneumonia bacteria, are a significant cause of bacterial meningitis in the U.S. highlighted the significant health burden posed by this bacterium. As infectious diseases threaten public health, there is a growing need for effective vaccination strategies, driving the demand for conjugate vaccines.

Another crucial factor driving the conjugate vaccines market is the rising regulatory approvals for new conjugate vaccine products. The increasing number of regulatory approvals expands the market and drives innovation within the industry. Companies are encouraged to develop novel conjugate vaccines to address unmet medical needs and target emerging infectious diseases. For Instance, in June 2024, the U.S. FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine for adults, to prevent invasive and pneumococcal disease. This approval marks a significant milestone in the fight against pneumococcal infections, which can lead to serious health issues and even death, especially among high-risk groups such as the elderly and those with specific pre-existing health problems.

Governmental initiatives and immunization programs worldwide have significantly influenced the growth of the conjugate vaccines market. For Instance, the WHO recommended including Pneumococcal Conjugate Vaccines (PCVs) in childhood immunization programs globally. Specifically, countries with high rates of childhood mortality, such as an under-5 mortality rate exceeding 50 deaths per 1000 births, should prioritize the introduction of these multicomponent PCVs.

Increasing emphasis on preventive healthcare practices among individuals and healthcare providers drives the demand for vaccines that offer long-term protection against infectious diseases. Conjugate vaccines, with their ability to enhance immune responses, align well with this preventive healthcare approach.

Global Conjugate Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global conjugate vaccine market report on the basis of product, brand, disease, pathogen, patient, and region

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Monovalent Conjugate Vaccine
• Multivalent Conjugate Vaccine
• Brand Outlook (Revenue, USD Million, 2018 - 2030)
• Prevnar
• Synflorix
• PedvaxHIB
• Hiberix
• ACT-HIB
• Pentacel
• Menveo
• Menactra
• MenQuadfi
• VAXNEUVANCE
• CAPVAXIVE
• Others
• Disease Outlook (Revenue, USD Million, 2018 - 2030)
• Pneumococcal
• Influenza
• DTP
• Meningococcal
• Typhoid
• Pathogen Outlook (Revenue, USD Million, 2018 - 2030)
• Bacterial
• Viral
• Combination
• Patient Outlook (Revenue, USD Million, 2018 - 2030)
• Pediatric
• Adults
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Brand
  • 1.2.3. Disease
  • 1.2.4. Pathogen
  • 1.2.5. Patient
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Brand outlook
  • 2.2.3. Disease outlook
  • 2.2.4. Pathogen outlook
  • 2.2.5. Patient outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Conjugate Vaccines Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of infectious disease
    • 3.2.1.2. Regulatory Approvals
    • 3.2.1.3. Government Initiatives and Immunization Programs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Conjugate Vaccine
    • 3.2.2.2. Stringent Regulatory Requirements
• 3.3. Conjugate Vaccines Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Conjugate Vaccines Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Conjugate Vaccines Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Monovalent Conjugate Vaccine
    • 4.4.1.1. Monovalent conjugate vaccine market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Multivalent Conjugate Vaccine

4.4.1.2.1. Multivalent conjugate vaccine market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Conjugate Vaccines Market: Brand Estimates & Trend Analysis

• 5.1. Brand Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Conjugate Vaccines Market by Brand Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Prevnar
    • 5.4.1.1. Prevnar market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Synflorix
    • 5.4.2.1. Synflorix market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. PedvaxHIB
    • 5.4.3.1. PedvaxHIB market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Hiberix
    • 5.4.4.1. Hiberix market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. ACT-HIB
    • 5.4.5.1. ACT-HIB market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Pentacel
    • 5.4.6.1. Pentacel market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Menveo
    • 5.4.7.1. Menveo market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Menactra
    • 5.4.8.1. Menactra market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.9. MenQuadfi
    • 5.4.9.1. MenQuadfi market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.10. VAXNEUVANCE
    • 5.4.10.1. VAXNEUVANCE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.11. CAPVAXIVE
    • 5.4.11.1. CAPVAXIVE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.12. Others
    • 5.4.12.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Conjugate Vaccines Market: Disease Estimates & Trend Analysis

• 6.1. Disease Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Conjugate Vaccines Market by Disease Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Pneumococcal
    • 6.4.1.1. Pneumococcal market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Influenza
    • 6.4.2.1. Influenza market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. DTP
    • 6.4.3.1. DTP market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Meningococcal
    • 6.4.4.1. Meningococcal market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Typhoid
    • 6.4.5.1. Typhoid market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Conjugate Vaccines Market: Pathogen Estimates & Trend Analysis

• 7.1. Pathogen Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Conjugate Vaccines Market by Pathogen Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Bacterial
    • 7.4.1.1. Bacterial Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Viral
    • 7.4.2.1. Viral market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Combination
    • 7.4.3.1. Combination market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Conjugate Vaccines Market: Patient Estimates & Trend Analysis

• 8.1. Patient Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Conjugate Vaccines Market by Patient Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Pediatric
    • 8.4.1.1. Pediatric Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Adults
    • 8.4.2.1. Adults market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Conjugate Vaccines Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2023 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. North America
  • 9.5.2. U.S.
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Canada
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Mexico
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. Europe
  • 9.6.2. UK
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ Reimbursement
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Germany
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/ Reimbursement
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. France
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/ Reimbursement
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Italy
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/ Reimbursement
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Spain
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Denmark
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/ Reimbursement
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Sweden
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.9. Norway
    • 9.6.9.1. Key country dynamics
    • 9.6.9.2. Regulatory framework
    • 9.6.9.3. Competitive scenario
    • 9.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Asia Pacific
  • 9.7.2. Japan
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ Reimbursement
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. China
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ Reimbursement
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. India
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ Reimbursement
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. Australia
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/ Reimbursement
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. South Korea
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/ Reimbursement
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.7. Thailand
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework/ Reimbursement
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Latin America
  • 9.8.2. Brazil
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/ Reimbursement
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. MEA
  • 9.9.2. South Africa
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/ Reimbursement
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. Saudi Arabia
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/ Reimbursement
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. UAE
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/ Reimbursement
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.5. Kuwait
    • 9.9.5.1. Key country dynamics
    • 9.9.5.2. Regulatory framework
    • 9.9.5.3. Competitive scenario
    • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2023
  • 10.3.4. Bavarian Nordic
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Others benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Bharat Biotech
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Others benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Biological E. Ltd.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Others benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Bio-Med
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Others benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. CSL Limited
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Others benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. GSK plc
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Others benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. GSPBL
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Others benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Merck & Co., Inc.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Others benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Novartis AG
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Others benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Pfizer, Inc.
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Others benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Sanofi
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Others benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. Serum Institute of India Pvt. Ltd.
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Others benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Taj Pharmaceuticals Ltd.
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Others benchmarking
    • 10.3.16.4. Strategic initiatives